|1.||Kinders, Robert J: 1 article (02/2014)|
|2.||Park, Sook Ryun: 1 article (02/2014)|
|3.||Jeong, Woondong: 1 article (02/2014)|
|4.||Choyke, Peter: 1 article (02/2014)|
|5.||Rapisarda, Annamaria: 1 article (02/2014)|
|6.||Kummar, Shivaani: 1 article (02/2014)|
|7.||Turkbey, Baris: 1 article (02/2014)|
|8.||Steinberg, Seth M: 1 article (02/2014)|
|9.||Chen, Alice: 1 article (02/2014)|
|10.||Melillo, Giovanni: 1 article (02/2014)|
11/01/2008 - "In efficacy studies, tumor reduction was found in nude mice implanted with DU145 cells treated with EZN-2968. "
02/01/2014 - "Adult patients with refractory advanced solid tumors were administered EZN-2968 as a 2-h IV infusion at a dose of 18 mg/kg once a week for three consecutive weeks followed by 3-week off; in a 6-week cycle. "
02/01/2014 - "Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors."
02/01/2014 - "This trial provides preliminary proof of concept for modulation of HIF-1α mRNA and protein expression and target genes in tumor biopsies following the administration of EZN-2968."
02/01/2014 - "We conducted a trial of EZN-2968 in patients with refractory solid tumors to evaluate antitumor response and to measure modulation of HIF-1α mRNA and protein levels as well as HIF-1 target genes. "
|3.||Glioblastoma (Glioblastoma Multiforme)
11/01/2008 - "In vitro, in human prostate (15PC3, PC3, and DU145) and glioblastoma (U373) cells, EZN-2968 induced a potent, selective, and durable antagonism of HIF-1 mRNA and protein expression (IC(50), 1-5 nmol/L) under normoxic and hypoxic conditions associated with inhibition of tumor cell growth. "
|1.||Messenger RNA (mRNA)
|2.||RNA (Ribonucleic Acid)